Latest From vasopharm GmbH
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
Small German firm, Vasopharm, wants to be the first company to bring a therapeutic treatment to the European market for use in patients with traumatic brain injuries – but getting the drug through Phase III studies alone will be its biggest test yet.
Emerging Company Profile: With mononuclear stem cell therapy from University of Texas research, new company hopes to address traumatic brain injury by reducing the pro-inflammatory cytokine cascade, which exacerbates the initial injuries in severe TBI.
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
- Therapeutic Areas
- Neurology, Nervous System
- vasopharm Biotech GMBH
- Western Europe
- Parent & Subsidiaries
- vasopharm GmbH
- Senior Management
Christian Wandersee, CEO
Frank Tegtmeier, PhD, CSO
- Contact Info
Phone: (49) 931 35 90 99-0
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.